Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06988904

ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ

Background: Obesity is a prevalent multifactorial disease worldwide and has become a significant public health concern. The latest data from the 2022 Catalonia Health Survey show that 56.2% of men and 43.7% of women are overweight or obese, and 39% of children aged 6 to 12 years have excess weight. Excess adiposity poses a health risk as it is associated with various chronic diseases such as type 2 diabetes mellitus, hypertension, and dyslipidaemia, all of which affect quality of life and increase mortality risk.

Hypothesis: The Energy2MOB obesity management programme in Berguedà is a group-based intervention incorporating nutrition education and physical activity. It aims to reduce excess body weight and the risk of chronic diseases, including type 2 diabetes mellitus, dyslipidaemia, and hypertension, through a multicomponent approach that enhances dietary habits, physical activity, and emotional eating regulation.

Objectives

* Assess the effectiveness of the Energy2MOB programme in reducing body weight by 5-10% among adults with obesity in the Berguedà health region. * Measure lifestyle modifications, including dietary habits, physical activity, and emotional eating.

Methodology: A randomised clinical trial with two groups (control and intervention) over one year, including individuals aged 18-65 years in the Berguedà health region with overweight grade II (BMI 27-30 kg/m²) or obesity (BMI 30-40 kg/m²). Exclusion criteria include significant language barriers, previous bariatric surgery, moderate to severe cognitive impairment, and severe psychiatric disorders preventing participation in sessions. Participants must attend at least 80% of the programme.

Measurements

* Sociodemographic factors: sex, age, education level, marital status, employment status. * Lifestyle factors: alcohol and tobacco use, dietary habits, physical activity, emotional eating, health-related quality of life. * Anthropometric parameters: body weight, height, BMI, waist circumference. * Blood pressure, medication use, biochemical parameters (fasting glucose, glycated haemoglobin, lipid profile, liver and kidney function markers, C-reactive protein).

Statistical Analysis: Accepting an alpha risk of 0.05 and a statistical power above 0.8 in a bilateral contrast, 68 subjects per group are required to detect a difference of at least 2.5 kg. A common standard deviation of 4.77 is assumed, with an estimated 15% dropout rate. Sample size calculations were performed using GRANMO version 8.0 (https://www.datarus.eu/ca/aplications/granmo/; consulted in November 2024).

Expected Outcomes, Applicability, and Relevance: This study aims to generate scientific evidence on the effectiveness of multicomponent group-based interventions focused on improving nutrition, physical activity, and psychological well-being in obesity and chronic disease management. It seeks to create an environment that facilitates behavioural changes, leading to weight reduction and improved quality of life. The findings will also contribute to the development of a practical guide for addressing excess weight in primary healthcare settings.

Keywords (maximum 6): Adult obesity, primary health care, group interventions, dietary interventions, multicomponent interventions, Mediterranean diet.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Unitat de Suport a la Recerca de la Catalunya Central, Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, Manresa, Spain, Manresa, Barcelona 08242

Manresa, Barcelona, 08242, Spain

Location contact

Anna Ruiz Comellas

CONTACT

[email protected]

+34626999007

Anna Ruiz Comellas

SUB_INVESTIGATOR

Cristina Vaque Crusellas

SUB_INVESTIGATOR

Mar Gargallo Civil

CONTACT

+34 660274434

About this study

BACKGROUND AND CURRENT STATE OF THE TOPIC Obesity is a chronic, complex, and prevalent disease worldwide, posing a significant public health concern with high socio-economic costs. The World Health Organization (WHO) defines it as an abnormal or excessive accumulation of fat that impairs health, promotes medical complications, and reduces life expectancy.

Recent studies indicate that obesity prevalence has risen in recent years and is projected to continue increasing. According to a recent study by the Carlos III Health Institute in collaboration with the Spanish Agency for Food Safety and Nutrition (AESAN) and regional health services, 55.8% of adults are overweight (63.7% of men and 48.4% of women), and 18.7% have obesity (19.3% of men and 18.0% of women). Among children and adolescents, 10.7% have obesity, and 30% are overweight. More specifically, the 2022 Catalonia Health Survey reports that half of the population aged 18-74 years has excess weight, including overweight and obesity, with 56.2% of men and 43.7% of women affected. Among children aged 6-12 years, nearly 39% have excess body weight, with 25.2% classified as overweight and 13.7% as obese.

There is no doubt that modern society fosters an obesogenic environment, promoting sedentary lifestyles and unhealthy diets dominated by processed foods. However, additional factors predispose individuals to excess weight even without exposure to these obesogenic influences. Obesity is a multifactorial disease, involving both intrinsic (non-modifiable) factors such as genetics and physiological causes and extrinsic (modifiable) factors such as environmental, psychological, social, economic, and political influences.

Physiopathologically, obesity is characterised by chronic low-grade inflammation due to adipose tissue dysfunction caused by excessive and/or abnormal fat accumulation. Excess adiposity is a major health risk as it is associated with a broad range of chronic diseases, including cardiovascular disease, type 2 diabetes mellitus, certain cancers, mental health disorders, chronic kidney disease, musculoskeletal complications, respiratory diseases, and non-alcoholic fatty liver disease (NAFLD). Addressing this issue with evidence-based solutions is urgent and a public health priority.

Expert groups, including the National Institutes of Health, WHO, the Academy of Nutrition and Dietetics, and the Spanish Society for the Study of Obesity (SEEDO), recommend a 5-10% reduction in initial body weight over six months to achieve health benefits and manage obesity-related comorbidities. Such weight loss is associated with reductions in body mass index (BMI), waist circumference, and fat mass, alongside significant improvements in glucose levels, lipid profile, and blood pressure. Consequently, obesity reduction strategies offer substantial benefits for chronic disease management, particularly type 2 diabetes mellitus, dyslipidaemia, and hypertension.

Beyond its impact on physical health, obesity also affects emotional, psychological, and social well-being. Weight-related stigma, discrimination, and bias contribute to decreased quality of life and increased obesity-related comorbidities. Current scientific evidence highlights that body weight regulation is not solely under voluntary control, as biological, genetic, and environmental factors play fundamental roles in obesity development and maintenance. Ineffective weight loss outcomes, insufficient multidisciplinary coordination, a lack of human and economic resources for obesity management, and societal misperceptions about obesity-particularly in lower socioeconomic groups-contribute to the overburdening of healthcare systems, preventing comprehensive and high-quality patient care.

Therefore, obesity treatment must adopt a holistic approach to achieve long-term health and well-being improvements. The focus should shift from mere weight reduction to sustainable lifestyle changes, including dietary modifications, increased physical activity, and psychological well-being improvements. Effective intervention requires a multidisciplinary team of specialists (e.g., dietitians-nutritionists, physicians, nurses, psychologists, and physical activity experts) working collaboratively to enhance patient health and well-being.

More specifically, interventions should promote a well-balanced diet alongside regular physical activity and behavioural therapy to sustain long-term lifestyle changes. The Mediterranean diet, a well-established cardioprotective dietary model in the region, serves as the basis for this approach. It emphasises a high intake of natural plant-based fats (extra virgin olive oil and nuts), minimally processed plant-based foods (vegetables, fruits, legumes, and whole grains), limited meat consumption (especially red and processed meats), moderate fish and egg consumption, and minimal intake of ultra-processed foods high in saturated fats, trans fats, and added sugars.

Regular physical activity and exercise are crucial in obesity treatment as they enhance weight loss, reduce abdominal fat, support weight maintenance, improve well-being, and positively impact cardiovascular risk factors. Psychological therapy plays an essential role, incorporating motivational strategies, problem-solving techniques, stimulus control, and stress reduction techniques. The COM-B behaviour change model will underpin the multicomponent group education intervention, ensuring participant motivation and engagement throughout all obesity treatment phases-critical for achieving successful outcomes.

Although several scientific studies have demonstrated the effectiveness of lifestyle modification-based group interventions, their implementation in primary healthcare settings remains limited due to a shortage of trained professionals with adequate availability. This highlights the need for resource allocation to address the issue effectively. Developing and implementing specific programmes based on a collaborative and interdisciplinary care model is crucial for successfully managing obesity and its associated health consequences. Such initiatives could improve the prevalence of cardiometabolic risk factors in affected individuals.

In 2021, the Catalan primary healthcare system incorporated dietitians-nutritionists through the Programme for the Promotion of Healthy Eating and the Prevention and Management of Diseases in Primary and Community Healthcare. These professionals focus on preventing and treating nutrition-related health issues by promoting healthy and sustainable eating habits tailored to individual conditions, risks, diseases, preferences, and socio-economic and cultural circumstances, with a particular focus on vulnerable populations. Additionally, primary healthcare introduced other roles, such as emotional well-being and community health specialists and physiotherapists, to facilitate the implementation of such programmes.

This project builds on prior obesity management interventions in primary healthcare settings, incorporating insights from past participants to refine and enhance its effectiveness. It has the potential to generate robust evidence on the effectiveness of multicomponent group-based interventions for obesity and chronic disease management in adults, providing a supportive environment that fosters sustainable behaviour change for improved patient quality of life and optimal health outcomes. If the intervention proves successful, a practical guide will be developed for broader implementation across primary healthcare centres addressing adult obesity.

HYPOTHESIS Participation in the Energy2MOB group education programme for obesity management in Berguedà will lead to a reduction in body weight among individuals with overweight or obesity. Additionally, it will improve dietary habits, physical activity levels, and emotional eating behaviour, while also supporting the management of chronic diseases such as type 2 diabetes mellitus, dyslipidaemia, and hypertension.

OBJECTIVES Primary Objectives (PO)

  • PO1: To assess the effectiveness of the Energy2MOB programme in achieving a 5-10% reduction in body weight among adults with overweight or obesity in the Berguedà healthcare region.
  • PO2: To determine lifestyle changes related to adherence to the Mediterranean diet, regular physical activity, and improved emotional eating regulation.

Secondary Objectives (SO)

  • SO1: To evaluate changes in biochemical, anthropometric, and blood pressure parameters.
  • SO2: To analyse improvements in health-related quality of life, reduction in cardiovascular risk, and better management of comorbidities (hypertension, dyslipidaemia, and diabetes mellitus).
  • SO3: To examine the feasibility of implementing the programme by assessing adherence, fidelity, and participant satisfaction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-65 years
  • Overweight (BMI 27-30 kg/m²) or obesity (BMI 30-40 kg/m²)
  • Availability to attend at least 80% (6 out of 8) of the group sessions

Exclusion criteria

  • Significant language barriers (unable to communicate in Catalan or Spanish)
  • Previous bariatric surgery
  • Moderate to severe cognitive impairment
  • Severe psychiatric disorders preventing participation in group sessions

Treatment and study plan

Energy2MOB

Other

Intervention: The Energy2MOB programme will take place at three primary healthcare centres in Berguedà:

Baix Berguedà (Puig-Reig CAP) Berga Centre (Berga CAP) Alt Berguedà (Guardiola de Berguedà CAP)

The programme will include:

One pre-intervention visit 8 weekly group sessions One post-intervention visit One-month telephone follow-up In-person follow-ups at three and six months

The control group will continue with standard care at their usual primary healthcare centre and will only attend pre-intervention, post-intervention, and six-month follow-up visits. They will not receive group sessions or telephone follow-ups. If the Energy2MOB programme proves effective, control group participants will be invited to participate in the intervention sessions.

Primary outcomes

  1. Body weight changed

    Time frame: 1 year

    Body weight changed refers to the process of losing body weight, typically through a combination of diet, exercise, and lifestyle changes. It is aimed at changing excess body fat, improving health, and achieving a healthier body composition. This changed can vary depending on the individual's goals, metabolic rate, and overall health.

Secondary outcomes

  1. Body weight

    Time frame: 1 year

    Calibrated scale, measured with light clothing and without shoes, in kilograms

  2. Height

    Time frame: 1 year

    With stadiometer, mesured in metres

  3. Waist circumference

    Time frame: 1 year

    Measured at the level of the navel using a flexible measuring tape, in centimetres

  4. BMI (Body Mass Index)

    Time frame: 1 year

    Weight and height will be combined to report BMI in kg/m^2

  5. Obesity-Related Comorbidities

    Time frame: 1 year

    Hypertension, dyslipidaemia/hypercholesterolaemia, type 2 diabetes mellitus, Fibromyalgia, cardiovascular disease, sleep apnoea syndrome, Osteoarticular pathology, non-alcoholic fatty liver disease (NAFLD), urinary incontinence

  6. Medication Use

    Time frame: 1 year

    Medication used for comorbidities associated with obesity refers to drugs prescribed to manage health conditions that often occur alongside obesity, such as type 2 diabetes, hypertension, dyslipidemia, and sleep apnea. These medications help control the symptoms and prevent further complications related to these comorbidities.

  7. Blood Pressure (systolic and diastolic)

    Time frame: 1 year

    Blood pressure refers to the force exerted by circulating blood on the walls of blood vessels. It is measured in two values: systolic and diastolic.

    Systolic blood pressure is the higher number and represents the pressure in the arteries when the heart contracts and pumps blood.

    Diastolic blood pressure is the lower number and measures the pressure in the arteries when the heart is at rest between beats.

    Normal blood pressure is typically around 120/80 mmHg. Blood pressure higher than 130/80 mmHg is considered elevated or high, which can increase the risk of cardiovascular diseases, strokes, and kidney problems. Monitoring and managing blood pressure is essential for maintaining overall health, particularly in individuals with obesity or other risk factors.

  8. Fasting plasma glucose

    Time frame: 1 year

    Plasma glucose refers to the concentration of glucose (sugar) in the liquid component of blood. It serves as a primary energy source for the body's cells. Measuring plasma glucose is essential for diagnosing and monitoring metabolic conditions such as diabetes mellitus. Normal fasting levels typically range between 70 and 100 mg/dL.

  9. Glycated haemoglobin (HbA1c)

    Time frame: 1 year

    Glycated haemoglobin (HbA1c) reflects the average blood glucose levels over the past two to three months. It forms when glucose binds to hemoglobin in red blood cells. HbA1c is widely used to diagnose and monitor diabetes. Normal values are generally below 5.7%, with higher levels indicating poor long-term glucose control.

  10. Smoking status

    Time frame: 1 year

    Current smoker, former smoker, non-smoker

  11. Cardiovascular risk

    Time frame: 1 year

    Assessed using validated risk score tools, REGICOR calculator. TABLES FOR CALCULATING 10-YEAR CORONARY RISK: <5% Low risk, 5-9.9% Moderate risk, 10-14.9% High risk, ≥15% Very high risk

  12. Mediterranean diet adherence

    Time frame: 1 year

    Adherence to the Mediterranean diet through the validated MEDAS questionnaire: <9 low adherence, >= 9 good adherence

  13. Dietary habits evaluation

    Time frame: 1 year

    Eating behaviour questionnaire

  14. Physical activity level

    Time frame: 1 year

    International Physical Activity Questionnaire (IPAQ) short version. Results:

    • Low. They do not record physical activity, or they record it but it does not meet the medium or high categories.
    • Medium. Considers the following criteria: 3 or more days of vigorous physical activity of at least 20 minutes per day. 5 or more days of moderate-intensity physical activity or walking of at least 30 minutes. 5 or more days of any combination of light, moderate, or vigorous physical activity that reach a record of 600 METs-min/week.
    • High. This is a high category and meets the following requirements: 3 or more days of vigorous physical activity or that accumulate 1,500 METs-min/week. 7 or more days of any combination of light, moderate, or vigorous physical activity that reach a record of 3,000 METs-min/week.
  15. Emotional eating assessment

    Time frame: 1 year

    Emotional Eating Questionnaire (CCE) Garaulet. Scale scores: unemotional eater 0 to 5, mildly emotional eater 6 to 10, emotional eater 11 to 20, and highly emotional eater 21 to 30 points.

  16. Health-related quality of life

    Time frame: 1 year

    EuroQol-5D (EQ-5D) with Visual Analogue Scale (VAS): Improvement in Health-Related Quality of Life (HRQoL) after the intervention: an improvement in HRQoL is considered if there is a decrease in the EuroQol (EQ-5D) questionnaire score compared to the baseline. A set of values consists of weights that convert each EQ-5D health profile into a value on a scale anchored between 1 (meaning complete health) and 0 (meaning a condition as serious as death).

  17. Programme adherence

    Time frame: 1 year

    Based on participant attendance records

  18. Intervention fidelity

    Time frame: 1 year

    Nomber of participants with completion of planned activities in each session

  19. Programme satisfaction

    Time frame: 1 year

    Participant feedback survey

  20. Total cholesterol

    Time frame: 1 year

    Total cholesterol measures the overall amount of cholesterol in the blood, including LDL (bad), HDL (good), and other lipid components. It is an important marker for cardiovascular health. High levels are associated with an increased risk of heart disease and stroke. Desirable values are generally below 200 mg/dL.

  21. HDL cholesterol

    Time frame: 1 year

    HDL cholesterol (high-density lipoprotein) is known as the "good" cholesterol because it helps remove excess cholesterol from the bloodstream. Higher HDL levels are associated with a lower risk of cardiovascular disease. It plays a protective role in heart health. Optimal levels are typically above 60 mg/dL.

  22. LDL cholesterol

    Time frame: 1 year

    LDL cholesterol (low-density lipoprotein) is often referred to as the "bad" cholesterol because high levels can lead to plaque buildup in the arteries, increasing the risk of cardiovascular disease. It is a key marker in assessing heart health. Optimal levels are typically below 100 mg/dL.

  23. Triglycerides

    Time frame: 1 year

    Triglycerides are a type of fat (lipid) found in the blood, used by the body for energy. High levels can increase the risk of cardiovascular disease, especially when combined with low HDL or high LDL cholesterol. Normal fasting levels are typically below 150 mg/dL.

  24. Alanine aminotransferase (ALT)

    Time frame: 1 year

    Alanine aminotransferase (ALT) is an enzyme primarily found in the liver that helps convert proteins into energy for liver cells. Elevated ALT levels in the blood may indicate liver damage or inflammation. Normal values typically range from 7 to 56 U/L.

  25. Aspartate aminotransferase (AST)

    Time frame: 1 year

    Aspartate aminotransferase (AST) is an enzyme found in the liver, heart, muscles, and other tissues. It plays a role in amino acid metabolism. Elevated AST levels can indicate liver injury or damage to other organs. Normal levels usually range from 10 to 40 U/L.

  26. Gamma-glutamyl transferase (GGT)

    Time frame: 1 year

    Gamma-glutamyl transferase (GGT) is an enzyme primarily found in the liver and bile ducts. It is involved in the metabolism of glutathione and the transport of amino acids. Elevated GGT levels are commonly used as a marker of liver disease, alcohol consumption, or bile duct obstruction. Normal values typically range from 0 to 30 U/L.

  27. Creatinine

    Time frame: 1 year

    A waste product produced by muscles from the breakdown of creatine. It is filtered by the kidneys, and elevated levels in blood can indicate impaired kidney function.

  28. Glomerular Filtration Rate (GFR)

    Time frame: 1 year

    A measure of kidney function that indicates how well the kidneys are filtering waste from the blood. It is calculated based on factors like age, sex, and creatinine levels.

  29. C-reactive Protein (CRP)

    Time frame: 1 year

    A protein produced by the liver in response to inflammation. High levels of CRP in the blood can indicate inflammation or infection in the body.

Study contacts

Contact information is provided by the study sponsor or research team.

Mar Gargallo Civil

CONTACT

[email protected]

+34 660274434

Sponsors and collaborators

Lead sponsor

Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina

Other

Registry information

Official study title

EFFECTIVENESS OF THE GROUP-BASED NUTRITION EDUCATION PROGRAMME FOR OBESITY MANAGEMENT IN BERGUEDÀ: A RANDOMISED CLINICAL TRIAL. ENERGY2MOB STUDY

Acronym: ENERGY2MOB

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 25, 2025
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.